Retatrutide + SLU-PP-332 Stack for Fat Loss and Performance Optimisation

Overview

The combination of compounds that control the energy balance and the appetite is an experimental frontier in the changing world of metabolic biohacking. A GLP-1/GIP/Glucagon receptor agonist, Retatrutide and an experimental ERR agonist SLU-PP-332 coupled with mitochondrial activity and endurance performance is one of such combinations.

The 6-week self-experiment that was reported in which low-dose Retatrutide was used together with SLU-PP-332 indicates that the combination might have a synergistic effect, i.e. it leads to better fat loss, better energy, and better muscle preservation with fewer side effects than Retatrutide alone.

Why This Stack Gained Attention?

Retatrutide has attracted attention due to its strong weight-loss properties, which tend to be more effective than other incretin-based drugs such as Semaglutide and Tirzepatide.

 Nevertheless, most of the users complain of fatigue, nausea, and muscle depletion as a result of appetite suppression and low energy intake. On the contrary, SLU-PP-332 also acts on cellular metabolism, stimulating energy expenditure, endurance and mitochondrial activity with minimal effect on reducing appetite. By synthesising the two, users hypothesise the existence of a balance between metabolic activation and appetite regulation, in which one compound counters the constraint of the other.

Stack Details

Compound	Role in Stack	Reported Dosage	Key Purpose
Retatrutide	GLP-1/GIP/Glucagon receptor agonist	1 mg/week (low dose)	Appetite suppression, fat metabolism
SLU-PP-332	ERR (Estrogen-related receptor) agonist	100 mg/day	Mitochondrial activation, muscle preservation, and endurance

The idea:

• Retatrutide reduces energy intake and enhances metabolic rate.
• SLU-PP-332 increases cellular energy output and preserves lean tissue.

Together, they may create a “dual-action” effect: improved performance despite calorie restriction.

Reported 6-Week Results

Week	Key Changes	Observations
Week 1–2	-6 lbs	No nausea, elevated energy, longer workouts (45 to 90 min)
Week 3–4	-8 lbs (total -14 lbs)	Strength increased, leaner physique, visible abs, veins
Week 5–6	-5 lbs (total -19 lbs)	Exceptional endurance, near elimination of soreness

Performance Notes

• Bench press PR increased from 405 lbs to 495 lbs
• All lifts up 10 to 15%
• Estimated body fat dropped from 15% to under 9%

These results suggest that this stack may stimulate both aesthetic and athletic outcomes simultaneously.

Why the Combination May Work?

Mechanism	Retatrutide Alone	SLU-PP-332 Alone	Combined Effect
Appetite Control	Strong	Weak	Balanced intake regulation
Energy Levels	Low (fatigue common)	High	Sustained alertness, better workouts
Muscle Preservation	Limited	Strong	Preserved or gained lean tissue
Fat Oxidation	Strong	Moderate	Accelerated fat loss
Side Effects	Nausea, GI upset	Minimal	Nearly absent

• Retatrutide controls “input” (less eating)
• SLU-PP-332 enhances “output” (more energy use)

Reported Side Effects

The most significant claim of the report was that there were no adverse effects in a mixture of two compounds. This is a pointer of SLU-PP-332 being able to reverse mitochondrial fatigue induced by Retatrutide - possibly through the enhancement of cellular respiration and ATP generation. However, they are anecdotal claims that cannot be supported by clinical evidence.

Symptom	Retatrutide Alone	With SLU-PP-332
Nausea	7/10	0/10
Fatigue	6/10	0/10
GI Discomfort	5/10	1/10

Cost Comparison

Regimen	Estimated Cost	Notes
Retatrutide Alone	~$500/month	Higher dose, more side effects
Retatrutide + SLU-PP-332 Stack	~$300/month total	Lower dose Retatrutide + full SLU-PP-332 dosing

Key Takeaways

• Synergistic Potential: Appetite suppression + metabolic activation: enhanced body recomposition.
• Muscle Retention: SLU-PP-332 may counter muscle loss from GLP-1 therapy.
• Energy Boost: Users report dramatically improved endurance and recovery.
• Caution Required: Both compounds are research-grade and lack long-term safety data.
• Cost Efficiency: Lower total expense with superior subjective results.

References

1. (2025). Available at: https://www.reddit.com/r/Biohackers/comments/1oj5xqf/i_stacked_slupp332_with_lowdose_retatrutide_and/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button (Accessed: 3 November 2025).
2. Peptide Q&A #5 – RETA + TRT, SLU-PP-332 Dosing by Peptide of The Week (2025) Spotify for Creators. Available at: https://creators.spotify.com/pod/profile/peptide-of-the-week/episodes/Peptide-QA-5--RETA--TRT--SLU-PP-332-Dosing-e37s14u (Accessed: 3 November 2025).
3. Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K. and Tsioufis, K. (2025) Retatrutide-A Game Changer in Obesity Pharmacotherapy, Biomolecules. U.S. National Library of Medicine. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/ (Accessed: 3 November 2025).